CrystalO Bio Completes Tens of Millions RMB Series A Financing with Riemann Hypothesis as Exclusive Financial Advisor

Recently, Shenzhen Jingdan Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jingdan Bio” or the “Company”) announced the completion of its Series A financing round, raising tens of millions of RMB. This round was led by Triwise Capital, with existing shareholders Longmen Capital and TECHNOLOGY FINANCIAL GROUP continuing to increase their investments.Riemann-Hypothesis Once Again Serves as the Exclusive Financial Advisor for This Round of FinancingQ.

Jingdan Bio, established in 2019, is a pharmaceutical company dedicated to the research and development of innovative ion channel therapies for neuropsychiatric disorders and chronic kidney disease. The company’s core team hails from Harvard University and the Shanghai Institute of Materia Medica, and it has also invitedDr. Erwin Neher, Nobel Laureate and pioneer in the field of ion channels, has joined as Chief Scientific Advisor.The company has established globally unique technology platforms for ion channel-targeted small-molecule and protein therapeutics—the IonFire platform (for small-molecule drugs) and the BigC platform (for large-molecule drugs)—supported by four core tool platforms: novel ion channel target discovery, activity assays, protein structure elucidation, and large-molecule drug development. This integrated infrastructure creates a robust technical moat, addressing industry bottlenecks such as low drug discovery success rates and significant side effects. The strengths of these technology platforms have earned Jingdan Bio high recognition from the investment community and multinational pharmaceutical giants. The proceeds from this financing round will be primarily used to advance the R&D of its core pipeline and accelerate collaborations with multinational pharmaceutical companies.

Dr. Jin Zhang, Founder of Jingdan BiologyStatement: We express our sincere gratitude for the team’s sustained efforts and the trust and support of our investors. The Company will continue to uphold a spirit of boldness in risk-taking and innovation, focusing on the field of ion channel therapeutics to tackle key challenges in drug development for neuropsychiatric disorders, chronic kidney disease, and cardiovascular diseases. By leveraging our “Platform + Pipeline” strategic model, we aim to address critical pain points in ion channel drug development, such as “undruggable” targets and significant side effects. We are committed to developing blockbuster drugs with global competitiveness, striving to establish Jingdan Biotech as a globally leading innovator in ion channel-based therapeutics.

Guochuang Triwise Health Industry Fund Team“We are delighted to participate in Jingdan Bio’s Series A financing. Unlike many classic drug targets, ion channels represent a class of notoriously ‘undruggable’ targets with substantial unmet clinical needs. The entire field remains a blue-ocean market. Developing therapeutics against such challenging targets requires the establishment of a comprehensive suite of technological tools. Jingdan Bio has long been active in this space, having built its proprietary IonFire and BigC platforms and achieved a fully closed-loop system for ion channel drug discovery and development. The company has also cultivated a portfolio of valuable and promising pipelines, attracting attention from multinational pharmaceutical companies. These factors underpin our strong confidence in Jingdan Bio’s sustained rapid growth in the future.”

Wang Haining, Founding Partner of Longmen Capitalstated: “We are delighted to increase our investment in Jingdan Biology’s Series A round, reflecting our continued confidence in the company’s growth. From the previous round to the current one, the company has achieved new technological breakthroughs and completed the establishment of several core technology platforms, thereby building a strong competitive moat. It is particularly encouraging that the company’s key pipeline assets have attracted significant attention from multinational pharmaceutical companies, with promising prospects for major collaborative R&D partnerships in the near term—a rare and highly anticipated development.”

Liu Yang, Partner at TECHNOLOGY FINANCIAL GROUPstated: “As existing shareholders, our decision to inject additional capital is based on our strong confidence in the future development of Jingdan Biology. There is a substantial unmet clinical need in the fields of neuropsychiatric disorders and chronic kidney disease, which hold the potential to yield blockbuster drugs worth billions of dollars. Jingdan Biology has established significant technical barriers and first-mover advantages in the field of ion channels. We believe that the company is poised to achieve major breakthroughs in these areas.”

Dr. Li Chaoxing, Chairman of Riemann-Hypothesis, as a shareholder of the company and the exclusive financial advisor for this round of financingstated: “Jingdan Bio possesses keen technical insight and strategic direction, along with continuous, efficient technological iteration and innovation, which is truly impressive. Jingdan Bio is also one of the very few companies globally to have a drug R&D platform specifically targeting ion channels, giving it an absolute first-mover advantage in this field and enabling the consistent generation of exciting first-in-class (FIC) pipeline candidates. Currently, drug development for neuropsychiatric disorders and chronic kidney disease still faces significant challenges, representing a highly untapped blue-ocean market with substantial clinical needs and market potential.”

Shenzhen Qianhai Triwise International Capital Management Co., Ltd.Established in October 2015, Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (Triwise Capital) brings together senior executives from renowned venture capital firms such as Shenzhen Capital Group, industry veterans from leading pharmaceutical companies like Roche and GSK, as well as research experts from prestigious academic institutions both in China and abroad. Guided by the philosophy of “returning investment to the real economy and leveraging capital to serve industries,” Triwise Capital strategically builds an industrial ecosystem, emphasizing original and value-driven investments. By leveraging resources from key industrial and technological platforms—including the National Innovation Center for High-Performance Medical Devices, the Institute of Synthetic Biology at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and the Shenzhen Jiyin Institute for Biomedical Translation—Triwise Capital focuses on investing in frontier technologies such as innovative drugs, synthetic biology, and high-end medical devices. The firm collaborates with industrial teams through a “co-entrepreneurship” model, utilizing financial strength to facilitate the commercialization of scientific achievements. Notable portfolio companies include Akeso Inc. (09926.HK), Transwarp (688031.SH), Anhui Yihong Pharmaceutical Co., Ltd. (688176.SH), Quanxin Biotechnology (02509.HK), Innovent Micropharma, Fitus Biotech, and Northcore Life Sciences, among others. Triwise Capital has received numerous accolades, including being ranked among the “Top 30 Best Venture Capital Firms in the Guangdong-Hong Kong-Macao Greater Bay Area” by China Venture and listed among the “Top 30 VC Firms Most Preferred by LPs in China” in 2023.

Longmen Capital is a specialized venture capital firm in the pharmaceutical industry, with team members holding backgrounds in medicine or biology and possessing extensive experience in pharmaceutical investment and industry operations. Longmen Capital has invested in more than 40 innovative pharmaceutical companies and manages funds totaling RMB 2 billion. Adhering consistently to the principles of independent research and value discovery, Longmen Capital serves as an early-stage investor for many innovative enterprises.

TECHNOLOGY FINANCIAL GROUP specializes in venture capital investment management, project investment management, and investment project planning and consulting. The company’s investment team comprises nearly 50 professionals and has executed over 100 investment cases. Its portfolio of companies that have achieved direct listings includes Huafeng Micro-Technology, Hongqiang Shares, Jiacheng International, Saifutian, Keshun Waterproofing, and Guangdong Hongtu.

Riemann-Hypothesis, founded by Dr. Li Chaoxing upon his return to China from the United States, is a boutique investment bank focused on “institutionalized” industrial innovation across the full lifecycle of the life sciences sector. Adhering to its original mission of partnering with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations to co-create the future, Riemann-Hypothesis is dedicated to providing investment incubation and “full-service” boutique banking solutions for original and pioneering biomedical projects worldwide. It has fully established its proprietary “institutionalized” empowerment system, breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.